Skip to main content

Table 2 Patients’ background

From: Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer

Variables Total Low NLR (<3.37, n = 36) High NLR (≥3.37, n = 12) p value
Age (yr) 70.5 (71.33 ± 6.92) 70 (70.7 ± 7.2) 73.5 (73.3 ± 5.9) 0.234
iPSA (ng/mL) 82.2 (605.1 ± 1446.3) 82.2 (436.2 ± 1090.7) 102.1 (1111.7 ± 2186.0) 0.322
Pathological Grade     
 Gleason’s Sum ≤ 6 2 (4.2 %) 1 (2.8 %) 1 (8.3 %) 0.156
 Gleason’s Sum = 7 14 (29.2 %) 13 (36.1 %) 1 (8.3 %)
 Gleason’s Sum ≥ 8 32 (66.7 %) 22 (61.1 %) 10 (83.3 %)
Clinical T Stage     
 2 6 (12.5 %) 4 (11.1 %) 2 (16.7 %) 0.501
 3 27 (56.3 %) 22 (61.1 %) 5 (41.7 %)
 4 15 (31.3 %) 10 (27.8 %) 5 (41.7 %)
Clinical N Stage     
 0 21 (43.8 %) 16 (44.4 %) 5 (41.7 %) 0.867
 1 27 (56.3 %) 20 (55.6 %) 7 (58.3 %)
Clinical M Stage     
 0 13 (27.1 %) 12 (33.3 %) 1 (8.3 %) 0.091
 1 35 (72.9 %) 24 (66.7 %) 11 (91.7 %)
NLR 2.49 (2.93 ± 1.66) 2.17 (2.25 ± 0.64) 4.26 (4.98 ± 2.08) <0.001
  1. median (mean ± SD)